针对异常RNA拼接在髓状恶性瘤中的治疗策略
Leora Boussi1, Jeetayu Biswas1,2, Omar Abdel-Wahab1,2
1Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
British journal of haematology
|October 15, 2024
概括
向异常RNA拼接为急性骨髓性白血病 (AML) 和骨髓质综合征 (MDS) 等骨髓性疾病提供了一种新的治疗策略. 这种方法解决了在当前向治疗不足的情况下实现持久缓解的挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 大规模测序确定了造血干细胞中的可向突变,从而产生了针对复发性/耐药性急性髓性白血病 (R/RAML) 的新药.
- 尽管取得了进展,但AML和高风险骨髓质疏松综合征 (HR-MDS) 的持久缓解仍然具有挑战性,需要新的治疗策略.
- 异常RNA拼接越来越被认为是髓状瘤恶性病的关键驱动因素,促进瘤发生和治疗耐药性.
研究的目的:
- 审查治疗策略,针对异常RNA拼接在骨髓性疾病.
- 探索拼接调制作为AML和MDS的新型治疗方法的潜力.
- 突出各种血液癌症中结合体突变的临床相关性.
主要方法:
- 关于RNA拼接,髓状瘤和向治疗的当前文献的综述.
- 在AML和MDS中对结合体组分突变 (SF3B1,SRSF2,U2AF1,ZRSR2) 的作用的分析.
- 探索旨在纠正异常拼接的治疗策略.
主要成果:
- 结合体蛋白的突变在AML中常见 (在MDS中高达60%),以及其他血液癌症.
- 异常拼接通过失调的基因表达,免疫逃避和化疗耐药性,有助于癌症的进展.
- 针对异常拼接,为新的治疗干预提供了一个有希望的途径.
结论:
- 对异常RNA拼接的调制代表了血液恶性瘤的有前途的治疗前沿.
- 对剪接向疗法的进一步研究可以显著改善AML和MDS患者的治疗结果.
- 了解结合体突变的影响对于开发有效治疗方法至关重要.
相关概念视频
RNA Splicing
56.1K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.1K
Alternative RNA Splicing
21.0K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Chromatin Structure Regulates pre-mRNA Processing
7.0K
In eukaryotic cells, nascent mRNA transcripts need to undergo many post-transcriptional modifications to reach the cell cytoplasm and translate into functional proteins. For a long time, transcription and pre-mRNA processing were considered two independent events that occur sequentially in the cell. However, it has now been well established that transcription and pre-mRNA processing are two simultaneous processes that are precisely regulated inside the cell.
The chromatin structure, especially...
The chromatin structure, especially...
7.0K
RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K


